Search results for "Cellular motility"

showing 4 items of 4 documents

Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome.

2007

Peters, T.A./0000-0001-8443-5500; van Beersum, Sylvia E.C./0000-0002-4552-2908; Cremers, Frans/0000-0002-4954-5592; Roepman, Ronald/0000-0002-5178-8163 WOS: 000247619800019 PubMed: 17558407 Protein- protein interaction analyses have uncovered a ciliary and basal body protein network that, when disrupted, can result in nephronophthisis ( NPHP), Leber congenital amaurosis, Senior- Loken syndrome ( SLSN) or Joubert syndrome ( JBTS)(1-6). However, details of the molecular mechanisms underlying these disorders remain poorly understood. RPGRIP1- like protein ( RPGRIP1L) is a homolog of RPGRIP1 ( RPGR-interacting protein 1), a ciliary protein defective in Leber congenital amaurosis(7,8). We show t…

AdultMaleHealth aging / healthy living [IGMD 5]Eye DiseasesGenetics and epigenetic pathways of disease [NCMLS 6]TMEM67Molecular Sequence DataMembrane transport and intracellular motility [NCMLS 5]Biologymedicine.disease_causeJoubert syndromeCell LineGenomic disorders and inherited multi-system disorders [IGMD 3]NephronophthisisCerebellar DiseasesGeneticsmedicinePerception and Action [DCN 1]Basal bodyAnimalsHumansNeurosensory disorders [UMCN 3.3]CiliaAdaptor Proteins Signal TransducingRenal disorder [IGMD 9]GeneticsMutationCiliumCiliary transition zoneProteinsSyndromemedicine.diseasePedigreeRatsCytoskeletal ProteinsGenetic defects of metabolism [UMCN 5.1]RPGRIP1LFemaleKidney DiseasesFunctional Neurogenomics [DCN 2]Ciliary Motility Disorders
researchProduct

Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.

2010

Abstract Ongoing clinical trials are exploring anticancer approaches based on signaling by TRAIL, a ligand for the cell death receptors DR4 and DR5. In this study, we report on the selective apoptotic effects of multivalent DR5 binding peptides (TRAILmim/DR5) on cancer cells in vitro and in vivo. Surface plasmon resonance revealed up to several thousand-fold increased affinities of TRAILmim/DR5-receptor complexes on generation of divalent and trivalent molecules, the latter of which was achieved with a conformationally restricted adamantane core. Notably, only multivalent molecules triggered a substantial DR5-dependent apoptotic response in vitro. In tumor models derived from human embryoni…

Cancer ResearchMembrane transport and intracellular motility [NCMLS 5]Apoptosis[CHIM.THER]Chemical Sciences/Medicinal Chemistry[ SDV.CAN ] Life Sciences [q-bio]/CancerTNF-Related Apoptosis-Inducing LigandMice0302 clinical medicineStilbenesReceptorCells Cultured0303 health sciencesDrug Synergism[ CHIM.THER ] Chemical Sciences/Medicinal ChemistryLigand (biochemistry)Tumor Burden3. Good healthMitochondrial medicine [IGMD 8]Oncology030220 oncology & carcinogenesisColonic NeoplasmsFemaleOligopeptidesSignal Transductionmedicine.medical_specialtyProgrammed cell deathBlotting WesternMolecular Sequence DataMice Nude[SDV.CAN]Life Sciences [q-bio]/CancerCell Line03 medical and health sciencesIn vivoInternal medicinemedicineAnimalsHumansAmino Acid Sequence030304 developmental biologybusiness.industrySurface Plasmon ResonanceHCT116 CellsAntineoplastic Agents PhytogenicXenograft Model Antitumor AssaysIn vitroReceptors TNF-Related Apoptosis-Inducing LigandEndocrinologyResveratrolCell cultureApoptosisCancer cellCancer researchbusiness
researchProduct

Chemotaxis and Haptotaxis on Cellular Level

2018

Chemotaxis and haptotaxis have been a main theme in the macroscopic study of bacterial and cellular motility. In this work, we use a successful model that describes cellular motility and investigate the influence these processes have on the shape and motility of fast migrating cells. We note that, despite the biological and modelling differences of chemotaxis and haptotaxis, the cells exhibit many similarities in their migration. In particular, after an initial adjustment phase, the cells obtain a stable shape, similar in both cases, and move with constant velocity.

Constant velocityMotilityChemotaxisCellular motilityBiologyCellular levelLamellipodiumHaptotaxisCell biology
researchProduct

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consens…

2008

Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands. Methods: Medical oncologists, urological surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference, and incorporated the new data into updated and revised guidelines. As for the first meeting, the methodology of evidence-based medicine (EBM) wa…

MaleMESH: Combined Modality TherapyBiopsyConsensus Development Conferences as Topic030232 urology & nephrologyMembrane transport and intracellular motility [NCMLS 5]MESH: Biopsy0302 clinical medicineStage I SeminomaMESH: Practice Guidelines as TopicMedicineSocieties MedicalMESH: Testicular NeoplasmsConsensus conferenceMESH: Neoplasm StagingNeoplasms Germ Cell and EmbryonalPrognosisPrimary tumorCombined Modality Therapy3. Good healthEurope030220 oncology & carcinogenesisPractice Guidelines as TopicMESH: Neoplasms Germ Cell and Embryonalmedicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]ConsensusUrologyMESH: Societies MedicalMEDLINEMESH: Prognosis03 medical and health sciencesSDG 3 - Good Health and Well-beingTesticular NeoplasmsInterventional oncology [UMCN 1.5]HumansMESH: ConsensusTesticular cancerNeoplasm StagingGynecologyMESH: Humansbusiness.industryMESH: Consensus Development Conferences as Topicmedicine.diseaseMESH: MaleClinical trialGerm cell cancerFamily medicineGerm cell tumorsMESH: EuropebusinessEuropean Urology
researchProduct